

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10559146
Filing Date	2005-12-05
First Named Inventor	ALEXANDER A. KHROMYKH
Art Unit	1648
Examiner Name	Agnieszka Boesen
Attorney Docket Number	45930.5.1

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button. **Add**

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							

NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10559146
Filing Date	2005-12-05
First Named Inventor	ALEXANDER A. KHROMYKH
Art Unit	1648
Examiner Name	Agnieszka Boesen
Attorney Docket Number	45930.5.1

1	Varnavski et al, "Noncytopathic flavivirus replicon RNA-based system for expression and delivery of heterologous genes" Virology 255, pp 366-375 (1999)	<input type="checkbox"/>
2	Nunes Duarte dos Santos et al., "NONCYTOPATHIC FLAVIVIRUS REPLICON RNA-BASED SYSTEM FOR EXPRESSION AND DELIVERY OF HETEROLOGOUS GENES", 2000, Virology 274, p. 292-308	<input type="checkbox"/>
3	Hunt et al., "DETERMINANTS IN THE ENVELOPE E PROTEIN AND VIRAL RNA HELICASE NS3 THAT INFLUENCE THE INDUCTION OF APOPTOSIS IN RESPONSE TO INFECTION WITH DENGUE TYPE 1 VIRUS", 2001, J. Virol. Methods. 97, p. 133-149	<input type="checkbox"/>
4	Konishi et al., "GENERATION AND CHARACTERIZATION OF A MAMMALIAN CELL LINE CONTINUOUSLY EXPRESSING JAPANESE ENCEPHALITIS VIRUS SUBVIRAL PARTICLES", J Virol. 75, p. 2204-2212	<input type="checkbox"/>
5	Konishi & Fujii, "DENGUE TYPE 2 VIRUS SUBVIRAL EXTRACELLULAR PARTICLES PRODUCED BY A STABLY TRANSFECTED MAMMALIAN CELL LINE AND THEIR EVALUATION FOR SUBUNIT VACCINE", 2002, Vaccine. 20, p. 1058-1067	<input type="checkbox"/>
6	Khromykh, "REPLICON-BASED VECTORS OF POSITIVE STRAND RNA VIRUSES", 2000, Curr Opin Mol Ther. 2, p. 555-569	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.